Recent events
Recent events tied to this brand in public sources.
Back to profile37 entries · Page 2 of 2
2020
FDA approves Abbott HeartMate 3 for pediatric patients
The U.S. Food and Drug Administration approved updated labeling for Abbott's HeartMate 3 left ventricular assist device for use in pediatric patients with advanced refractory left ventricular heart failure.
2020
Abbott launches Similac Pro-Advance in Canada
Abbott launched Similac Pro-Advance infant formula with 2'-FL, described as the first product of its kind in Canada.
2020
Abbott launches FreeStyle Libre in India
Abbott announced the launch of its FreeStyle Libre continuous glucose monitoring system in India. The system is available to adults and children over four living with diabetes and to women with gestational diabetes.
2020
Abbott reports third-quarter 2020 results and raises guidance
Abbott announced its third-quarter 2020 financial results, reporting worldwide sales of $8.9 billion, and projected full-year adjusted diluted EPS of at least $3.55.
2020
FDA authorizes Abbott’s BinaxNOW COVID-19 antigen test
Abbott said it received Emergency Use Authorization from the U.S. Food and Drug Administration for its BinaxNOW COVID-19 Ag Card portable antigen test.
2020
FDA approves Abbott Patient Controller app for compatible Apple smartphones
Abbott received US Food and Drug Administration approval for use of its Patient Controller app on compatible personal Apple smartphone devices.
2020
FDA approves Abbott Gallant ICD and CRT-D devices
Abbott announced that the U.S. FDA approved its next-generation Gallant implantable cardioverter defibrillator and cardiac resynchronization therapy defibrillator devices.
2020
Abbott shifts some distribution channels to new distributors
Abbott said it would transfer some distribution channels to new distributors, affecting Meikang Bio's agency business for imported products.
2020
Abbott announces a planned increase in daily test production
Abbott said it was ramping up production with a plan to deliver 50,000 ID NOW COVID-19 tests per day to the U.S. healthcare system beginning the following week.
2020
Dignity Health launches rapid COVID-19 testing in Northern California
Dignity Health began rapid COVID-19 testing at six hospitals across Northern California, with results available in about 30 minutes. The service was described as a partnership with Abbott.
2020
Abbott unveils rapid coronavirus test
Abbott unveiled a portable coronavirus test that can detect infection in as little as five minutes. The company said it planned to supply 50,000 tests a day starting Wednesday.
2020
FDA authorizes Abbott COVID-19 test
The FDA issued an emergency use authorization to Abbott Laboratories for its COVID-19 molecular test.
2020
Abbott launches quadrivalent influenza vaccine in India
Abbott said it launched a new inactivated quadrivalent influenza vaccine in India, offering protection against four virus strains.
2020
Abbott receives CE Mark for Gallant devices
Abbott announced that it had received CE Mark for its Gallant implantable cardioverter defibrillator and cardiac resynchronization therapy defibrillator devices, enabling their introduction in Europe.
2020
FDA approves an alternative implantation technique for Abbott’s HeartMate 3
Abbott announced that the U.S. FDA approved an alternative, less invasive surgical technique for implanting its HeartMate 3 heart pump, allowing implantation through a lateral thoracotomy rather than open-heart surgery.
2019
Abbott and Omada partner to offer FreeStyle Libre through a diabetes care program
Abbott and Omada Health partnered to offer Abbott’s FreeStyle Libre continuous glucose monitoring system through Omada’s digital care program for people with type 2 diabetes. Omada will provide the combined solution to employers and health plans.
2019
Abbott announces plan to integrate FreeStyle Libre with Tandem insulin pump
Abbott announced plans to integrate its FreeStyle Libre system with Tandem Diabetes Care’s plug-and-play insulin pump. The companies were finalizing technical and commercial details; the integration had not been reported as completed.